UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and $6 price target The company has a potential blockbuster program with a CD47 combo currently in Phase II for metastatic breast cancer, the analyst tells investors in a research note. UBS sees ALX reporting a “robust” dataset in mid-2027, demonstrating CD47 inhibitor evorpacept’s efficacy in CD47 high and/or HER2+ metastatic breast cancer patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO: